Sensorium Therapeutics Raises $30 Million To Develop Nature-Inspired Psychoactive Mental Health Treatment

Sensorium Therapeutics closed a $30 million Series A financing round and will use the funds to advance its initial asset, SENS-01, using its Biodynamic Discovery Platform™ (BDP), as a psychoactive treatment for mental illness. The platform is a drug discovery engine that rapidly identifies, synthesizes, and enhances targeted molecules as novel therapeutics.

The company's initial asset, SENS-01, shows promise to deliver swift therapeutic effect for treating anxiety. Sensorium is developing SENS-01 as a rapid-acting and well-tolerated therapeutic for patients with anxiety and depression and expects to begin studies in 2023 and enter the clinic . . .